We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nestor Health. | NSR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 109.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 109.50 |
| Top Posts |
|---|
Posted at 05/10/2010 20:35 by trendfloor Just off the press floor........Nestor Healthcare jumps on talk of raise offer Nestor Healthcare was back in the spotlight amid talk that its suitor has significantly raised its takeover offer for the business. Published: 8:05PM BST 05 Oct 2010 The chatter is that Acromas, the company behind AA and Saga, has increased its bid for Nestor, down 3¼ to 86½p, from 90p a share to 100p. The move comes after Nestor rejected Acromas's offer of 90p a share in August. Sources said that although Nestor's board is now minded to recommend Acromas's offer, some shareholders are keen for the business to hold out for a price of between 105p and 110p a share. Indeed, The Sunday Telegraph revealed that Acromas has been holding tentative negotiations with Allied Healthcare after it appointed advisers from US investment bank Oppenheimer to look at "strategic options" for the group. Sources, though, cautioned that Acromas has yet to make a formal offer for Allied Healthcare. Overall, the FTSE 100 jumped by 79.79 points to 5635.76 and the FTSE 250 surged by 118.15 points to 10681.96. Joshua Raymond, market strategist at City Index, said: "Better-than-expecte British Airways climbed to the top of the blue-chip leaderboard after better-than-expected traffic figures. The airline's shares surged 15½ to 254.6p after it revealed a 1.3pc increase in revenue passenger kilometres for September, helped by an increase in first and business-class travel. The rise is the biggest gain since August 2008, the month before the collapse of Lehman Brothers. Citigroup upgraded technology group Invensys to "buy", which helped the shares gain 9.2 to 307.2p. Mark Fielding, an analyst at Citigroup, said: "Concerns over its late cycle nature and the risks to growth in rail have weighed on the shares over the last year. However, our analysis suggests continued growth... at rail. When this is combined with recovery continuing across the rest of the portfolio we see renewed attractions in the share." InterContinental Hotels Group advanced 19p to £11.46 as JP Morgan Cazenove gave the stock a push on valuation grounds. Tim Barrett, an analyst at JP Morgan Cazenove, said: "The outlook for 2011 is favourable and likely to be an increasing focus for investors after Marriott and Starwood publish 2011 guidance with their third-quarter results. We believe low supply growth in 2011 is likely to support [revenue per available room] growth of between 5pc and 8pc in 2011." BT Group put on 2.7 to 148½p amid talk Ofcom will this week announce a decision on superfast broadband that is likely to be favourable to the telecoms company. Tui Travel rallied 9.1 to 225.9p after it said in a trading update that it had a good summer and bookings were picking up. Elsewhere in the sector, rival Thomas Cook increased 6.7 to 179¾p. Hedge fund group Man Group perked up 9½ to 227.1p after it said its Athena Guaranteed Futures rose 0.55pc last month and had risen 10.5pc over the past 12 months. Gold mining stocks were in vogue as the price of the precious metal flirted with a fresh high. Randgold Resources climbed 195p to £66.55. Rising risk appetite gave base metal mining companies and banking stocks a lift. Anglo American put on 103½p to £26.41 and Barclays edged up 9 to 308.8p. Aviva advanced 3.4 to 396.2p despite the fact that Bank of America Merrill Lynch argued that the latest "bid" related spike in the transport group's shares will unwind as the likelihood of any corporate activity lessens. On a less positive tack, Inmarsat fell 26 to 629p. After the market closed yesterday, Harbinger Capital confirmed it had sold 65m shares - about 14pc of the company at 630p a share in a move that raised £410m. The share sale was larger than expected and triggered speculation Harbinger could sell the rest of the its holding once the 180-day lock-up expires. Among the smaller companies, Computacentre jumped 22.9 to 322.9p as Investec upgraded the stock to "buy" from "hold". "We believe earnings quality has improved through operational efficiencies, managed services traction and cost savings. The outlook suggests a continuation of these trends, reasonable revenue progress and modest forecast momentum," said Julian Yates, an analyst at Investec. "Buy" advice from Barclays Capital lifted Carphone Warehouse 3¼ to 266p. Karen Howland, an analyst at Barclays Capital, said: "We expect Carphone Warehouse to report another set of strong figures during its second-quarter results on November." Homeserve also rallied 17.1 to 459.1p after Credit Suisse took up coverage with an "outperform" rating and a 720p price target. Analysts at Credit Suisse said: "HomeServe offers one of the most compelling combinations of growth, profitability and value in Europe." Weir Group put on 33p to £14.86 as Bank of America Merrill Lynch argued it is likely to offer "superior growth" in an economic cycle that is "settling down". However, oil services company Wood Group slipped 3.3 to 424.6p as Morgan Stanley downgraded it to "equalweight". "The recovery we identified in engineering as the key 'swing factor' for its earnings recovery in 2011 is being priced in," said Martjin Rats, an analyst at Morgan Stanley. Vallar, Nat Rothchild's investment vehicle, is still trading below its issue price of £10.00 a share. When Vallar floated in July, investors had high hopes for the financier's plans to consolidate some of the mining sector. However, Vallar, up 15 to 920p, has failed to carry out a transaction since its float and some investors are preparing to kick up a fuss if the shares fail to move higher. |
Posted at 31/8/2010 09:35 by miikke Interesting- is this game-playing by market makers, small investors losing their nerve or some other explanation?Any thoughts anyone? |
Posted at 22/8/2010 17:12 by bojangles141 A month on and Nestor is up by 30%A month ago, Midas Extra, our subscription-only column, recommended Nestor Healthcare. The company is mainly involved in the supply of care workers for elderly and disabled people at home. It provides services ranging from helping pensioners dress themselves to round-theclock care for those with severe mental or physical disabilities. the group also operates a range of primary healthcare services, including out-ofhours surgeries, walk-in centres and dentists. The business has been doing well, figures have been resilient during the recession and analysts predict a 30% increase in pre-tax profits this year to £11.2m and an 18% increase in the dividend to 2.6p. In July, the shares were trading at 67p, at which point they seemed undervalued. Some followers have been concerned about the impact of the Government's forthcoming spending review on Nestor's fortunes, as most of its care worker business comes from local authorities. But the elderly need looking after, their numbers are growing and taking care of them at home is considerably cheaper than keeping them in hospital. Chief executive John Ivers is confident about nestor's future prospects - and he is not alone. On August 11, the group revealed it had received a 90p-a-share approach from Acromas Holdings, the private equity group that owns insurer and travel group Saga and the AA. nestor rejected the approach as too low, but Acromas is expected to seek discussions directly with shareholders. Midas verdict: Nestor shares have risen to 88p since the approach became public so they are 30% up in a month. Institutional investors Gartmore and Schroders each hold 29% and hold the key to Nestor's future. At this stage, Acromas has three options - walk away, raise its bid or make its offer formal and hope for the best. Shareholders who bought last month should sell a third of their shares at current levels, just in case the bid comes to nothing. Potential investors should hold fire and buy if Acromas walks away. Mail On Sunday - 22nd August 2010 |
Posted at 16/6/2010 13:08 by kimball808 Noticed Gartmore have increased their holing to 29% over the last few months. Not sure whether Schroders have off loaded their 29% stake to gartmore. Awaiting to here back from Nestor investor relations. Any thoughts on a bid in the making? |
Posted at 19/1/2010 23:16 by miikke Maybe too many people are buying with no real justification other than hope of an easy buck. The market makers will be laughing at these private investors very soon; so my view is be careful. DYOR. |
Posted at 12/8/2008 09:42 by nickcduk According to Dow Jones newswire we should have had results today from NSR. The fact that we haven't could have spooked a few investors into selling this morning. DJN were also wrong about WNER reporting a trading statement yesterday so they are fallible. |
Posted at 31/7/2008 13:56 by miikke Has it gone quiet just before the announcement? Investors here have been disappointed before so it could go either way. Any views? |
Posted at 08/1/2008 17:22 by victorskulicz Here are five shares that look interesting on a 12-month view, some of which I own as medium to long-term plays. Together they are a mix of 'growth' and 'recovery' stocks, with the consistent factor being an attractive risk/reward profile. I should add the caveat that each stock carries with it an aspect of speculation regarding likely events to deliver value, and so things could turn out differently. These shares are also prone to volatility but that should be a bonus if you know what you are doing.Dana Petroleum (DNX) An astute business model and strong oil prices have helped Dana graduate to the FTSE 250 from the small cap index and the business looks set for continued progress. Dana's risk/reward is attractive because it combines strong production assets, mainly in the North Sea, with attractive exploration at home and abroad. The company is at the early stages of a major drilling programme that has started successfully and offers the prospect of 20 wells in 2008 - across the UK, Norway and Egypt. A share price of £13.90 may look dear but reflects Dana's progress in recent years and the intrinsic value is supported at lower oil prices than the current $90 or more. In practice oil prices, and therefore Dana's shares, are likely to remain volatile and so if holding such a share you should be steeled for at movements of at least 20% to 30% up or down in the near term. However, such volatility has been a backdrop to Dana shares multiplying in value eight times since 2002. Analysts look for pre-tax profit of £200m or better in 2008, implying a prospective P/E near 13 times relative to earnings growth over 30%. Operationally, Dana is at an exciting stage. The main risk for its shares is whether the speculative premium currently in oil prices, disappears, for example if the US slides into recession. But China and India appear to have their own momentum and oil supply issues continue to support prices. Despite the inherent volatility of oil, I feel comfortable holding this share in anticipation of further upside. See www.dana-petroleum.c Meldex (MDX) This specialty pharmaceutical group has developed and acquired an interesting range of mass market products. It is best known for 'dissolve-in-the-mou Meldex is at an exciting stage of its development and a spate of recent news about new products and institutions buying in, caught traders' imaginations. The shares surged from about 40p to above 90p then plunged after an update omitted to provide trading figures. The volatility looks like typical stockmarket noise until a company proves its earning power. A share price retreat to a low 50p range attracted buyers and the current level of 60p, capitalising Meldex at £116m, is interesting on a 12-month view (and longer). Break-even was achieved (on a normalised basis) during the first half of 2007; analysts project near £4m pre-tax profit for the year as a whole and near £10m in 2008 as commercialisation kicks in. With announcements hinting at further commercial progress in the New Year and beyond, Meldex is an interesting share for 2008. Pharmaceuticals may also come back into stockmarket fashion, should consumer businesses be hit by slowdown. I own a shareholding. Lookers (LOOK) Shares in this UK motor trader appear to have found a current support level at 105p after halving from 220p amid fears about consumer spending. I have recently noted how the directors have bought a substantial number of shares at higher prices than 108p, including the operations director and finance director - and they should be in good positions to judge the business. The concerted buying continues, with several directors adding on Christmas Eve at about 105p. Manifestly, they believe stockmarket pessimism is overdone, and it will be interesting to see how Lookers shares trend this year - as a test of whether you should take more notice of company directors or financial traders. Lookers is a fine business, strategically and operationally. See www.lookers.co.uk for more information. A main risk with following the directors is whether their perspective is affected by being involved in the near-term issues of the business, which look positive, whereas the stockmarket senses the medium-term inevitability of the business cycle biting. Cars represent 'discretionary spending' i.e. what can quite easily be avoided relative to essentials such as food. It is currently hard to be precise about what effect the ongoing credit crunch will have on personal also corporate spending, although the de-rating of some cyclical shares has already been brutal. Aided by close relations with manufacturing partners and a decentralised approach, Lookers achieved 6% like-for-like sales growth in the first half of 2007 against 2% for the wider market. The interim dividend rose 23% and the directors are piling in before Lookers enters its closed period ahead of its preliminary results. Taking a cautious view, if Lookers' profits remain flat in 2008, its shares now trade on a forward P/E of about 10 times. If the company can get anywhere near brokers' forecasts of £35m pre-tax profit then the P/E drops into single figures. There is uncertainty but in a portfolio context it may be worth engaging it, offsetting the risks via shares in unrelated industries. Superscape Group (SPS) At 8p currently, shares in the mobile games publisher appear to stand a fair chance of achieving upside, in relation to better trading and/or a takeover bid. The main risk is a consumer slowdown in the US where the now Californian-based business focuses its efforts. Since achieving the number five position in the US mobile games publishers' league, Superscape has received an approach "that may or may not lead to a recommended cash offer". This would need to be pitched much higher than the current market value of £16m (including about £5m balance sheet cash) if the business is genuinely at a turning point given that institutions have waited nearly three years after a rights issue and placing at 38p. Mobile games publishing can be fickle, however, and intense competition means no guarantee of a growth business. Although Superscape has yet to prove it is consistently cash-generative, it made a gross profit of £5.4m in the six months to the end of July 2007, so there is value for an acquirer after stripping out costs, in addition to tax losses to exploit. Hence at about 8p, the risk/reward profile is interesting. Even if the business fails to sparkle, this kind of level ought to provide support for a bid, while the growing momentum of games publishing and distribution arrangements currently points to useful upside. The progression of trading updates will be influential although these can vary in the near term. I own a shareholding. GCM Resources (GCM) Formerly Asia Energy also Global Coal Management, Aim-listed GCM may be poised for government approval to mine a substantial coal deposit in Bangladesh. As is frequently the case with 'resources nationalism' in developing countries, the project went on the back burner in 2006 after agitators whipped up opposition. But Bangladesh has a serious energy problem with relentless power cuts and the Asian Development Bank is pushing for the mine to go ahead; and GCM has worked steadily to build a consensus. There is a fair chance GCM's scheme of development could be approved sometime during 2008 and the shares re-rate from 98p currently. This is not a 'blue sky' gamble; the current share price has financial backing. At the end of June the company had nearly £17m balance sheet cash and a portfolio of investments that it has been successfully making while the management awaits approval of its mine development plan. Intrinsically, this limits downside risk to a few pence per share, with the stockmarket unwilling to ascribe much value to the intended Bangladesh coal mine. The chairman and a non-executive director recently added to their shareholdings, just above 100p, presumably because they believe terms can be agreed with the government of Bangladesh. This is the kind of mining play where governments can keep tripping up foreign investors, but Bangladesh cannot mine the resource independently and GCM has an existing contract backed by international law. I own a shareholding. This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser. |
Posted at 03/11/2006 10:04 by slapmeharder Is there a link to Peers Carter? The things that usually break here are the hearts of us investors.And who is Thomas William George Charlton who now owns 23.3 million Pinnacle shares (26%)? Slap |
Posted at 03/8/2005 10:05 by m.t.glass ...Nestor Healthcare's results were worse than analysts had expected with the most disappointing performance in from the social care division, which provides nurses to take care of the elderly in their own homes. On 11 times forward earnings with a prospective yield of 1.5%, the Telegraph sees no reason to buy. Nestor is on a hit list of stocks for some of the City's notorious short-sellers, adds the Independent. The reason is that Nestor needs to refinance its £105m overdraft facility, which runs out next year. It is as optimistic it can be done within a couple of months of choosing bankers, but investors should avoid the stock for a while.... (Sharecast, 3 Aug) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
